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a-linolenic omega-3 fatty acid for stroke protection: from
brain preconditioning paradigm to nutrition
Stroke and the failure of
neuroprotective agent
development
Stroke is the third leading cause of
death, annually afflicting approximately
150,000 French and 780,000 Ameri-
cans. On average in the developed
countries, stroke strikes once every 40
seconds and causes death every 4
minutes, with an estimated 25% death
rate within the first week, and 50% of
the patient population within 5 years
after the brain attack. Among survivors,
work capacity is compromised in 70%of
victims, among which 30% need assis-
tance with self-care. Stroke causes func-
tional control impairment, paralysis,
speech and sensory problems, memory
and reasoning deficits, often leading to
Abstract: Stroke is the third leading cause of death, due to its high incidence, the
severity of the insult, and lack of treatment options. The only therapeutic is restoration of
cerebral blood flow achieved by recombinant tissue plasminogen activator treatment,
but only approximately 5% of patients receive it. In addition, therapeutics aimed at
achieving neuroprotection by blocking the ischemic cascade, as identified in numerous
preclinical studies, failed in clinical trials. This failure in translation from experimental
models to clinical trials led to a re-evaluation of properties which would constitute the
‘‘best-in class’’ therapeutics to be used against stroke. Given that neuroprotection
appears ineffective per se, an emerging direction is to identify therapies, probably
combinatorial in nature, which protect the whole neurovascular unit and target time-
dependent neurotoxic mechanisms. Molecules that activate complex cellular signaling
cascades that render the brain resistant to subsequent ischemia, known as
preconditioners, offer a novel perspective in stroke protection. Preconditioning elicits
complex endogenous neuroprotective responses that act by pleiotropic mechanisms to
block death pathways, promote survival pathways and increase resistance. In addition to
chemical preconditioners, natural/endogenous compounds such as adenosine,
glutamate, lysophospholipids, and omega-3 polyunsaturated fatty acids have been
demonstrated to be excellent preconditioners. Consequently, a major new concept in
preconditioning to combat stroke is introduced, which is preconditioning achieved
through supplementation of an essential item in diet or as a nutraceutical. Several
epidemiologic studies suggested a beneficial effect of a seafood/omega-3-enriched diet
in cerebral diseases, but the omega-3-induced protective mechanisms are still poorly
identified. This review highlights how a-linolenic acid (ALA), the omega-3 polyunsa-
turated fatty acid precursor, protects the brain from in vivo and in vitro models of stroke,
thus potentially fulfilling the goal of identifying the ‘‘best-in class’’ therapeutics against
stroke. Also described is the surprising pleiotric nature of ALA in protecting neurons,
vasodilating brain arteries and stimulating neuroplasticity. Importantly, feasibility of
delivery has been demonstrated, since ALA supplementation can be achieved through
modification of the daily diet, for which prevention of stroke-induced mortality and
cerebral damage has been confirmed. Therefore evaluating ALA as an interesting
preconditioner against stroke represents a novel and extremely relevant concept in the
context of nutraceutical and functional food development.
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PUFA AND NEUROPROTECTION
long-term disability, dementia and post-
stroke depression. Hence stroke is a
global burden that affects all racial or
ethnic groups indiscriminately. Its social
and psychological costs are substantial in
developed nations, as well as its eco-
nomic cost, which have been estimated
to be greater than 70 billion dollars in
2010 in theUSA (Lloyd-Jones et al., 2010,
Rosamond et al., 2008).
In eighty five percent of stroke cases, the
neurovascular event causing the stroke
is ischemic, meaning that blood flow to
a part of the brain is disrupted due to
occlusion of a blood vessel. Occlusion
deprives the brain of nutrients and
oxygen, eliciting a complex interplay
of multiple cellular signaling pathways
that damages the neurovascular unit
(neuronal, glial and endothelial cells
(Iadecola, 2004)) within the affected
territory. Within the core of the ischemic
territory, blood flow is most severely
restricted, and excitotoxic and necrotic
cell death occurs within minutes. In the
periphery of the core, termed the
ischemic penumbra, reduced collateral
blood flow buffers the full effects of the
stroke. In this area, primarily apoptosis
leads to a slower rate of cell death
(Endres and Dirnagl, 2002).The only
therapeutic available is recombinant
tissue plasminogen activator, which
restores cerebral blood flow by disrupt-
ing the blood clot causing vessel
occlusion. Unfortunately, due to its
restricted application, thrombolysis it
is only perform in approximately 5% of
the stroke population. Other therapeu-
tics aimed at more directly blocking the
cellular ischemic cascade, as identified
in numerous preclinical studies, failed in
clinical trials. In 2007 O’Collins
reviewed 1026 neuroprotective treat-
ments identified for acute stroke
between 1957 and 2003. Of the 114
treatments which were tested (and
failed) in clinical trials, no drug perform
any better against all other drugs when
tested against focal models of cerebral
ischemia. In addition, these drugs dis-
played poor adherence to the series of
criteria determined to identify neuro-
protective agents with the best chance
of success in clinical trials by the Stroke
Therapy Academic Industry Roundtable
(STAIR). This poor translation from
experimental models to clinical trials
raised the question of whether the best
drugs were being chosen to proceed to
clinical trial, leading to consideration of
new ideas and recommendations for the
development of strategies in combating
stroke.
Regarding translation, much has been
written about timing and dosing, failure
to incorporate preclinical information
into clinical trials, as well as acknowl-
edgement that animal data may not
adequately support translation of a
neuroprotective drug to clinical
(Jonas et al., 1999). Although animal
models may not faithfully reproduce all
multifactorial aspects of strokes in
humans, animal models are representa-
tive of important clinically relevant
pathophysiological features of human
stroke. Therefore, the ‘‘best in class’’
drug should be tested and be efficient in
several experimental mode of stroke, as
well as in species which include pri-
mates. A second recommendation is to
redefine the view of the pathology as a
cerebrovascular and not exclusively as a
neuronal disease. Nowadays, consider-
ing only neurobiological aspects of
stroke defies increasing recognition that
stroke triggers both cerebral endothe-
lium dysfunction leading to CBF alter-
ation, and neuronal, astroglial and
oligodendroglial homeostasis disrup-
tion, as well as andmicroglial activation.
Therefore the research and medical
community had now moved towards
a more integrative view of stroke taking
in consideration the protection of all cell
types within the entire neurovascular
unit (fundamentally comprising endo-
thelium, astrocyte and neuron). In order
to be considered as a good candidate for
a clinical trial, stroke treatment must
have clear and demonstrable efficacy on
all the neurovascular unit cells or at least
must be carefully considered in terms of
its actions on all cell types and neuro-
vascular functions. Thus, an experimen-
tal drug should be better tested for
safety and efficacy not only in neurons
but also on cerebral endothelial cells,
astrocytes, oligodendrocytes, microglia
and so on (Lo and Rosenberg, 2009). A
large body of basic research over the
past two decades shows that ischemic
stroke causes brain damage by multiple
pathways, implicating mechanisms like
excitotoxicity, oxidative stress and pro-
grammed cell death. The failure of
stroke trials which targeted one or only
a few of these pathways suggests that
targeting a single element of a single
pathway may not yield sufficient neuro-
protection. Consequently, an emerging
view is that combination or « multi »
therapy, or discovering drugs exhibiting
multimodal actions atmultiple cell types,
is required to address the multifactorial
nature of stroke. Therefore, molecules
that provoke multiple protective and
regenerative mechanisms should be
particularly attractive therapeutic agents
(Lo, 2008; Minnerup and Schabitz,
2009; Zaleska, et al., 2009). A pertinent
and effective experimental approach to
identify such candidates would be to
betterunderstandhowthebrainprotects
itself against ischemia, through the study
of brain preconditioning.
Brain preconditioning is
an innovative approach
in discovery of novel
cerebroprotective
strategies against
ischemic stroke
This cellular and adaptative biological
process conferring resistance to ischemia
is called preconditioning. Particularly
within the last two decades, precondi-
tioning has attracted much interest
within the clinical and basic neuroscient-
ist communities, primarily due to pro-
motion of protection and regeneration
against stroke through direct and/or
indirect mechanisms, involving multiple
cell types. Therefore preconditioning is
considered pleiotropic in nature. Ische-
mic preconditioning of the brain, heart
and other organs refers to an endoge-
nous protective process that is induced
by a sublethal ischemia and which
increases the tissue tolerance to a sub-
sequent, normally lethal ischemia. Since
its original description in the brain by
Kitagawa in 1990, (Kitagawa et al.,
1990), non-ischemic peconditioners
including various sublethal insults like
epilepsy, endotoxins, anoxia, hyperther-
mia and spreading depression were
shown to also induce delayed tolerance
to normally lethal forms of themselves,
and additionally tolerance to ischemia,
alsonamed‘‘cross-tolerance’’ (Plamondon
et al., 1999; Tauskela and Blondeau,
2009).
A concern that potential clinical appli-
cations of brain preconditioning may be
very limited due to the requirement of
bringing neurons to the ‘‘brink of
death’’ during preconditioning, has
been circumvented by discoveries that
preconditioning and its tolerance to
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ischemia may be induced or mimicked
pharmacologically by chemicals like
adenosine and KATP channel agonists
(Blondeau et al., 2000). Several other
compounds including 3-nitropropionic
acid and the glutamate receptor ago-
nist, N-methyl-D-aspartate (NMDA)
have been investigated in both in vivo
and in vitro models of preconditioning
(Tauskela and Blondeau, 2009). More-
over, retrospective case-control studies
showed a clinical correlate of the
experimental preconditioning para-
digm, suggesting that patients with a
history of transient ischemic attack (TIA)
exhibit a decreased morbidity after
stroke (O’Duffy et al., 2007; Weih et
al., 1999), strongly suggesting that
preconditioning is a pertinent and
effective experimental concept in the
human brain. Finally, with the recent
demonstration that preconditioning
can also be induced by a variety of
natural product like polyunsaturated
fatty acid and lysophospholipids, pre-
conditioning studies provide an inno-
vative approach for the discovery of
novel cerebroprotective strategies
(Blondeau et al., 2002a; Blondeau et
al., 2002b).
Preconditioning induces two different
temporal windows of protection against
ischemia: the first window known as
‘‘rapid preconditioning’’ occurs within
minutes after the stimulus used for
induction of preconditioning and only
lasts for around1 h,whereas the delayed
window produces a more robust state of
protection that usually develops 24 h
after preconditioning induction, peaks at
72 hours fades 7 days later. In general, a
two- to four-day interval between pre-
conditioning and lethal ischemia pro-
vides the greatest protection, at least in
the rodent brain. Increasing this interval
generally reduces benefits, although in
some studies a delay of up to two weeks
could still result in some ischemic
tolerance. Longer stimulation with low
stimulation by non-ischemic precondi-
tioners, while still not inducing toxicity,
may generate more robust ischemic
tolerance. All these facts, the molecular
sensors, transducers and effectors of
preconditioning have been already ele-
gantly described in high-impact reviews
(Kirino 2002; Dirnagl et al., 2003; Gid-
day, 2006; Obrenovitch, 2008). These
reviews also underline key conceptual
differences between preconditioning
and neuroprotection strategy, notably
the time frame and mechanism of
protection. Preconditioning activates
endogenous pro-survival responses,
including genetic remodeling, to sup-
press the toxic signaling effects, whereas
drug therapies are mostly designed to
directly inhibit toxic signaling pathways
occurring post-stroke. Thus precondi-
tioning requires a certain delay in order
to attain the subsequent maximal pro-
tection, so it is often inadequately
perceived as a preventive strategy.
The preventive strategies
in stroke are aimed to
decrease stroke incidence
The poor translation from experimental
models to clinical trials has led to
adoption of additional strategies in
combating stroke,most notably drawing
attention to the importance of preven-
tion. The prevention or/and treatment of
the risk factors has emerged as a priority
to reduce the occurrence of stroke. Some
risk factors cannot bemodifiable, such as
a family history of cerebrovascular dis-
eases, aging, male sex, and Hispanic or
Black race (Allen andBayraktutan, 2008).
But the other risk factors including
cardiovascular complications (atrial fibril-
lation, valvular heart disease, ischemic
cardiomyopathy and carotid stenosis
for example), hypertension, diabetes,
hypercholesterolemia, cigarette smok-
ing, increased inflammatory markers,
dyslipidemia, and obesity may be
addressed by life-style changes and
pharmacologicals, to prevent or mini-
mize the possibility of having a stroke.
Modifiable risk factors often coexist and
havebeenestimated toaccount for60%-
80% of stroke incidence in the general
population (Allen and Bayraktutan,
2008; Moskowitz et al., 2010), and are
often associated with improper nutrition
causing imbalance in essential vitamins
and nutriments. Many clinical and epi-
demiologic studies have shown that
deficiency in vitamins, nutriments, and
essential omega-3 polyunsaturated fatty
acids may be risk factors of stroke per se.
Low levels of fruits and vegetables in diet
or improper omega-3 intake, both in the
form of a-Linolenic Acid (ALA) and the
Long Chain derivatives (LC-n-3), Eicosa-
Pentaenoic-Acid (EPA) and Docosa-Hex-
aenoic-Acid (DHA), are a risk factor for
cardiovascular and cerebral diseases,
including coronary heart disease and
stroke (Dauchet et al., 2005; deGoede et
al., 2011; Riediger et al., 2009; Simo-
poulos, 2008).
Importantly, besides reducing the risk of
stroke, these factors may exhibit a
protective role against stroke-induced
damage, a field of study of potentially
major relevance but inadequately
addressed. Several epidemiologic stud-
ies in cerebral diseases identified bene-
ficial effects of diets rich in omega-3
poly-unsaturated fatty acids (PUFAs) by
consumption of seafood (rich in LC-n-3:
EPA and DHA) and/or vegetable oils rich
in precursor (ALA), suggesting that
omega-3 PUFAs may have a neuro-
protective role. This notion received
mechanistic support with the discovery
that omega-3 activates the neuronal
potassium TREK-1 channel, leading to
neuronal membrane hyperpolarization.
Hyperpolarization of synaptic terminals
decreases glutamate release while
blocking NMDA receptor activation at
the post-synaptic level, a protective
strategywith proven efficiency in animal
model of stroke (Fink et al., 1998;
Lauritzen et al., 2000). Besides provid-
ing acute neuroprotection, our labora-
tories evaluate the possibly that omega-
3 FA may also act as a preconditioner
against ischemia. By fulfilling multiple
requirements of prevention, acute pro-
tection and preconditioning, acting at
multiple cell types, omega-3 FA may
indeed be recognized as a ‘‘best-in
class’’ therapeutic against stroke.
Omega-3 a-linolenic acid
as an acute treatment in
experimental model of
cerebral ischemia and
stroke
During the acute phase of ischemic
injury, glutamate excitotoxicity and
hyperactivation of its receptors are the
major destructive mechanisms within
the core and surrounding penumbra.
Chronologically, glutamate release-
driven neuronal death occurs within
minutes to hours following cerebral
ischemia, so therapeutics aiming to
inhibit this acute phase must be admin-
istered very shortly after the ischemic
insult. Of relevance, this time coursemay
match the first protectionwindowoccur-
ring within minutes to hours after the
induction of ‘‘rapid preconditioning’’.
The time constraints of acute neuro-
protection may be difficult to achieve in
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clinical practice, but testing a drug in
both paradigms is important in estimat-
ing its neuroprotective capacity.Wehave
therefore investigated neuroprotection
by ALA and DHA in an in vivo transient
model of global ischemia, in which
neuronal death of CA1 hippocampal
pyramidal cells is mainly driven by
glutamate excitotoxicity (Pulsinelli and
Brierley, 1979). Sevendays after a 20min
global ischemia, only 15% of the CA1
neurons survived the ischemic challenge,
while the injection of ALA (i.c.v., 10 mM/
5 mL) within 30 min post-ischemia
allowed 80% of the CA1 neurons to
survive. ALA was also protective
when administered intravenously (i.v.,
500 nmol/kg) 30minutes before or after
the ischemic challenge (figure 1A). How-
ever, in thismodel, EPAandDHAhad less
pronouncedand reproducible protective
effects (Lauritzen et al., 2000). We
therefore decided to focus our inves-
tigationon the omega-3precursor rather
than on the long chain derivates. To
clearly establish that ALA could inhibit
glutamate excitotoxicity we tested its
protective potential in an in vivomodel of
seizure induced by the administration of
the glutamate analog kainic acid, and in
an in vitro model of glutamate stress. In
vivo, using the same dosage paradigms
as for ischemia, ALAwas neuroprotective
when injected i.v. either 30min before or
after KA treatment (Lauritzen et al.,
2000). In vitro, the same rangeof concen-
trations known to be protective both in
vivo with i.c.v. injection and in vitro on
granule cells, prevented hippocampal
neuronal death triggeredby the addition
of an excitotoxic concentration of gluta-
mate (50 mM) for 24 hours (Blondeau
et al., 2009). In all these models a
saturated fatty acid, palmitic acid, failed
to induce any beneficial effects, under-
lying the importance of the omega-3
polyunsaturated class of fatty acids.
ALA effect on the vascular tone and CBF
was investigated. As previously dis-
cussed, the failures of therapeutics
targeting only neurons and the hyper-
acute nature of glutamate release-
driven neuronal death in ischemia lead
the scientific community to identify
drugs that could also help restoring
and/or preserving the cerebral blood
flow (CBF). The in vivo and in vitro
neuroprotective 10 mM and 100 mM
concentrations of ALA induced an
increase of the diameter of the basilar,
but not of the carotid artery (Blondeau
et al., 2007). In both mice and rats
(figure 1B) ALA acted as a vasoactive
drug, leading to an approximately 30%
increase of the diameter of the basilar
artery ex vivo, accounting for a 20%
increase of the in vivo CBF observed
within 30 min post-injection (i.v. neuro-
protective dose of 500 nmol/kg). Since
ALA did not dilate carotid arteries with
elastic properties, the omega-3 induced
relaxation appears to be specific to
cerebral resistance arteries such as those
of the cerebral vascular bed, without
affecting the systemic blood pressure.
Therefore, both the increased resistance
to glutamate hyperexcitability and vaso-
dilation capacity of brain arteries that
increases collateral flow and reduce CBF
loss in the penumbra, after ALA injec-
tion, may potentially contribute to
protection against ischemic stroke.
Thus, we investigated the effect of a-
linolenic acid in the middle cerebral
artery occlusion (MCAO) model, using
the intraluminal suture technique
ascribed to be the closest model to
human stroke.
The compatibility of ALA post-treatment to
the clinical setting was addressed by
investigating two clinically relevant
parameters. Thewindow of intervention
to efficiently reduce the infarct volume
24 hours post-MCAO was character-
ized, and a delivery protocol was
designed to improve the long-term
survival rate. ALA significantly reduced
the infarct volume when injected up to
6 h after reperfusion onset (Heurteaux
et al., 2006). Maximal protection was
achieved using 500 nmol/kg injected
2 h post-ischemia, and the window of
intervention faded by 12 hours after the
onset of reperfusion (figure 1C). The
ALA-induced neuroprotection corre-
lated with a decrease in cytopatholog-
ical features of cell injury, DNA-
fragmentation and pro-apoptotic Bax
protein up-regulation. For all parame-
ters used as a measure of the degree of
protection, the natural omega-3 pre-
cursor efficiency was similar to riluzole, a
chemical neuroprotectant currently in
clinical use for amyotrophic lateral
sclerosis. In contrast, the saturated
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Figure 1. Omega-3 a-linolenic acid decreases acute ischemic stroke damage. A) ALA intravenous
injection (i.v., 500 nmol/kg) 30 minutes before a ischemic challenge (20 min global ischemia)
prevents glutamate excitotoxicity-driven CA1 hippocampal neuronal death. B) Left panel: ALA is
vasoactive triggering a 30% release of the basilar artery diameter ex vivo. Right panel: In vivo a
20% increase of the CBF occurs within 30 min post ALA-injection (i.v. neuroprotective dose of
500 nmol/kg). C) ALA significantly reduces the infarct volume when injected up to 6 hours after
reperfusion post-MCAO. The maximal protection was achieved with a dose of 500 nmol/kg
injected 2 hours post-ischemia and the window of successful intervention faded 12 hours after
the onset of reperfusion.
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palmitic fatty acid failed to reduce the
infarct volume when injected 2 hours
after reperfusion. Interestingly, a single
ALA injection providing the best cere-
bral protection at 24 hours post-stroke
had no beneficial effect on the long-
term survival rate. To achieve a 3-fold
improvement in the survival rate at 10
days and one month post-ischemia,
repeated injections were required
(Blondeau et al., 2009, Heurteaux
et al., 2006). This data suggested that
the reduction of glutamate excitotox-
icity was insufficient to reduce long-
term mortality rates. Indeed, excitotox-
icity suppression may instead only delay
neuronal death, by failing to prevent
later stages of cell death including
apoptosis and associated inflammatory
events, events known to cause progres-
sive tissue damage hours to days or
weeks later. Nevertheless, the beneficial
effects caused by repeated injections
spaced several days apart implied that
ALA triggered other beneficial mecha-
nisms. Preclinical data indicate that
pharmacological therapies that enhance
brain-repair processes substantially im-
prove functional recovery when given
during the later recovery phase of stroke.
The concept underlying these restorative
therapies is the pleiotropic targeting of
many parenchymal cell types including
neural stem cells, cerebral endothelial
cells, astrocytes, oligodendrocytes, and
neurons leads to enhancement of neuro-
trophic factor production, endogenous
neurogenesis, angiogenesis, and synap-
togenesis in ischemic brain tissue (Zhang
and Chopp, 2009). These events collec-
tively improve stroke outcome including
neurological function.
To evaluate long-term benefits, the effect
of subchronic ALA administration on
neuronal plasticity was investigated. An
increase in neurogenesis was observed,
following three sequential injections
performed using the same time course
and dose that improved long-term
survival rate post-stroke (Blondeau
et al., 2009). Subchronic ALA treatment
significantly increased the number of
proliferating immature neurons, as
identified by the colocalization of incor-
porated BrdU, a DNA synthesis marker,
in dividing progenitor cells and DCX, a
microtubule-associated protein specifi-
cally expressed in all migrating neuronal
precursors. These immature neurons
identified 3 days after the last injection
survived and matured by 21 days after
the last ALA injection (figure 2A),
suggesting that the repeated ALA injec-
tions triggered the induction of neuro-
genesis. The upregulation of key
proteins involved in synaptic functions,
synaptophysin-1, VAMP-2, and SNAP-
25 as well as proteins supporting
glutamatergic neurotransmission, V-
GLUT1 and V-GLUT2, also indicated
that ALA subchronic treatment pro-
moted synaptogenesis (figure 2B). These
effects correlated with an increase in
BDNF protein levels both in vivo,
following subchronic ALA treatment
and in vitro using neural stem cells
and hippocampal cultures (Blondeau
et al., 2009). Altogether these results
imply a pleiotropic effect of ALA, which
could target different brain cell types
and combine acute neuroprotection,
CBF regulation and long-term repair/
compensatory plasticity to protect from
stroke. This pleiotropism parallels brain
preconditioning findings of combined
neuroprotective, regenerative and anti-
inflammatory effects.
Omega-3 a-linolenic acid
as a preconditioner in
experimental model of
cerebral ischemia and
stroke
As a proof a concept that ALA could be a
‘‘natural’’ preconditioner against cere-
bral ischemia, we tested whether ALA
preconditioning could trigger the late
phase of tolerance against two models
of excitotoxicity-driving neuronal death
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by global ischemia and kainic acid
injection. ALA injection (i.v., 500
nmol/kg) 3 days before 6 min global
ischemia or kainic acid-induced epilep-
tic seizure almost fully prevented the
CA1 neurodegeneration (Blondeau et al.,
2002b). The narrow temporal window
of cerebral protection conferred by
ALA preconditioning parallels findings
observed using preconditioning by ische-
mia or epileptic activity. Similarities in
signal transduction pathways activated
with ischemia and other well-established
chemical preconditioners, confirmed that
ALA may be studied as a new natural
preconditioner of the brain. For example,
ALA preconditioning induced the neuro-
protective HSP70 heat shock protein
within a similar time frame and neuronal
localization shared by ischemic, epileptic
and adenosine and Katp channel openers
preconditioning (Blondeau et al., 2000;
Blondeau et al., 2002b). In addition,
preconditioning by ALA, ischemic, kainic
acid-induced epileptiform activity rapidly
increased the expression of the tran-
scription factor nuclear factor-kB. NFkB
is an ubiquitously expressed inducible
regulator of a broad range of genes that
play pivotal roles in cell death and survival
pathways. The three different precondi-
tionings increased NFkB DNA-binding
activity and nuclear translocation of p65
and p50 subunits of NFkB in a similar
manner and cellular compartmentaliza-
tion (Blondeau et al., 2001). Pretreatment
with the NFkB inhibitor diethyldithiocar-
bamate or kB-decoy DNA suppressed the
increased DNA-binding activity and the
nuclear translocation of NFkB, leading to
the loss of the preconditioning-induced
neuroprotection against an otherwise
lethal ischemic or epileptic challenge.
Thus the functions of the pathways
established by ALA preconditionings
are similar to those observed in the other
preconditioning that are required for
the development of brain tolerance.
ALA preconditioning was also demon-
strated in mice, since ALA subchronic
treatment 3 days before a transient
focal ischemia significantly reduced the
infarct volume (Blondeau et al., 2009).
The similarities in the narrow window
of cerebral protection, as well as over-
lap in signal transduction pathways,
activated by ischemia and other
well-established chemical precondi-
tioners, clearly demonstrates that ALA
can trigger the ubiquitous pleiotropic
protective signaling pathways impor-
tant to brain preconditioning.
Omega-3 a-linolenic acid
as preconditioner in the
diet to prevent stroke-
induced damage: from
preconditioning toward
nutraceutical
The overall properties of ALA may fulfill
criteria necessary to rank this omega-3
PUFA as a good neuroprotectant, or at
least as a crucial molecule for brain
resistance. ALA is a fatty acid qualified
of ‘‘essential’’, because its synthesis is not
performed by the human organism and
must therefore be provided by diet. This
could explain in part why the severe
deficiency in omega-3 intake that has
been reported in numerous epidemio-
logic studies may weaken the brain,
representing an important risk factor in
the development and/or deterioration of
certain neuropathologies and neurovas-
cular diseases, like stroke. In the context
of stroke treatment, the rationale of
supplementation with a non-ischemic
preconditioner like ALA has seemed
promising to investigate, especially since
no detrimental effects of ALA have been
documented as far as we are aware. An
unobtrusive method of increasing ALA
intake would be to increase levels in the
daily diet. We addressed this important
hypothesis by investigatingwhether ALA
supplementation achieved using a diet
enriched in rapeseed oil, a rich source of
ALA as the only source of lipids,
decreased infarct volumes in stroked
mice. A diet enriched with ALA (0,75%
by weight) significantly reduced mortal-
ity rate, infarct size induced by 60min of
middle carotid artery occlusion and
increased the probability of spontaneous
reperfusion in the post-ischemic period
(Nguemeni et al., 2010). Figure 3 shows
that the ALA-enriched diet decreased the
total infarct volume by 35 to 45% (total
infarct, cortical infarct). The reduction of
the focal ischemic lesion was similar in
rats supplemented with high dietary
levels of long-chain omega-3 (1.75%
by weight) over 6 weeks (Relton et al.,
1993). This result implies that lower
levels of supplementation may be
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Figure 3. ALA-enriched diet decreases the infarct volume induced by 60 min MCAO. The upper
panel summarizes the 6-week diet protocol and the ALA content in the diet. The bottom panel
shows that the cerebroprotection occurs mainly at the cortical level.
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required when using precursors com-
pared to long-chain derivatives. Since
the neuronal protection obtained with
supplementation achieved force-feed-
ing fish oil rich in long-chain omega-3
is controversial (Bas et al., 2007; Ozen
et al., 2008), ALA provided by vegeta-
ble rapeseed oil should be considered
as an interesting alternative to long-
chain omega-3 derivates from fish oil.
Finally, a drastic reduction of lipid
peroxidation levels was also observed
in the ischemic brain of animals fed
the ALA enriched diet, suggesting
that beneficial effects of ALA have
not yet been exhaustively categorized
(Nguemeni et al., 2010).
Conclusion
To conclude, this review supports a-
linolenic acid as an omega-3 precursor
exhibitinginterestingpotentialtherapeu-
tic value against stroke.Moreover, a new
perspective in thepreconditioningfield is
offered. Specifically, a novel approach to
precondition the brain against ischemia
may be to implement existing or novel
nutraceuticals. Indeed, one could view
nutraceuticals as ‘‘natural precondi-
tioners’’ which target the brain to its
increase resistance against devastating
insults such as stroke. Ultimately, the
future of preconditioning largely de-
pends upon successful translation of
important findings to daily life and the
clinical arena. Development of strategies
achieved using functional food may
representanimportantavenuetoachieve
this goal.
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